Physician

Ahsan M Basha, MD

According to 2025 Medicare claims, Ahsan Basha, MD (NPI: 1043283849) practices hematology/oncology, with the plurality of this provider's patient population coming from Iroquois, IL. This provider's primary affiliated billing organization is RIVERSIDE HEALTH SYSTEM (NPI: 1417061193; TIN: 36-3167726) and primary practice location at 60970-1806. Basha is affiliated with the IRCCO (ACO ID: A2619) and CVS Accountable Care Organization, Inc. (ACO ID: D0061), participating under both the MSSP and REACH models.

Basha's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 426 traditional Medicare patients, billed 1,212 HCPCS/CPT codes, and received $87,014 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,575 prescription claims across 235 beneficiaries totaling $3,429,366 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 12 claims. Open Payments data shows 20 records totaling $415. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $742,791 to $3,429,366. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $5,401 and ending at $2,320.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	278	1,046	$76,167
2016	289	1,079	$75,094
2017	304	1,062	$76,693
2018	321	1,159	$76,623
2019	295	978	$74,825
2020	289	937	$78,309
2021	336	1,194	$117,232
2022	394	1,118	$107,316
2023	423	1,237	$91,594
2024	426	1,212	$87,014

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	88	756	$742,791
2016	90	665	$860,282
2017	105	800	$906,301
2018	97	912	$1,002,442
2019	77	584	$781,867
2020	81	709	$568,547
2021	98	871	$797,494
2022	169	1,058	$1,842,866
2023	197	1,338	$3,277,807
2024	235	1,575	$3,429,366

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	46	$5,215
2016	N/R	26	$2,271
2017	N/R	11	$259
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	54	$1,163
2021	N/R	55	$1,723
2022	N/R	12	$342
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	53	53	$133
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	61	164	$103
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	55	55	$87
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	223	645	$68
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	197	257	$44

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	62	1,687	$1,018,429
Cabometyx	Cabozantinib S-Malate	20	585	$451,023
Xtandi	Enzalutamide	31	930	$414,071
Lenalidomide	Lenalidomide	21	588	$343,571
Venclexta	Venetoclax	16	472	$184,409

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	20	$415	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ahsan M. Basha, MD?

Tedicare shows public-source Medicare data for Ahsan M. Basha, MD (NPI 1043283849), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ahsan M. Basha, MD have ACO affiliation data?

Ahsan M. Basha, MD is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619) and CVS Accountable Care Organization, Inc. (REACH, ACO ID D0061).

What billing organization is linked to Ahsan M. Basha, MD?

Ahsan M. Basha, MD is linked to RIVERSIDE HEALTH SYSTEM (billing NPI 1417061193) in the available physician profile data.

Does Ahsan M. Basha, MD have Open Payments data?

Ahsan M. Basha, MD has 20 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.